Measurement of HTL0016878 in Cerebrospinal Fluid
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 16
- Registration Number
- NCT04849286
- Locations
- π¬π§
MAC Clinical Research, Manchester, United Kingdom
Study to Investigate the Receptor Occupancy of HTL0014242 Using [18F] FPEB in Healthy Male Subjects
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 8
- Registration Number
- NCT04462263
- Locations
- π¬π§
Parexel Early Phase Clinical Unit, Harrow, Middlesex, United Kingdom
Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2021-04-29
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 71
- Registration Number
- NCT03785054
- Locations
- π¬π§
Covance, Leeds, West Yorkshire, United Kingdom
A Study to Assess Safety, Tolerability, and Efficacy of HTL0018318 in Patients With Dementia With Lewy Bodies
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Heptares Therapeutics Limited
- Registration Number
- NCT03592862
- Locations
- π―π΅
Kagawa Prefectural Central Hospital, Takamatsu, Japan
π―π΅Nishitaga Hospital, Sendai, Japan
π―π΅Kurumi Clinic, Tokyo, Japan
Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 60
- Registration Number
- NCT03456349
- Locations
- πͺπΈ
Syneos, Barcelona, Spain
A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2019-11-29
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 120
- Registration Number
- NCT03244228
- Locations
- π¬π§
Hammersmith Medicines Research, London, Hammersmith, United Kingdom
Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects
Phase 1
Completed
- Conditions
- Safety IssuesPharmacokinetics
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2017-06-26
- Last Posted Date
- 2017-09-07
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 54
- Registration Number
- NCT03198624
- Locations
- π¬π§
Richmond Pharmacology, London, London Bridge, United Kingdom
Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 37
- Registration Number
- NCT02958696
- Locations
- π¬π§
Hammersmith Medicines Research, London, United Kingdom
Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: HTL0009936 modified releaseDrug: HTL0009936 immediate release
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 14
- Registration Number
- NCT02710188
- Locations
- π¬π§
Quotient Clinical, Ruddington, Nottingham, United Kingdom
Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
Phase 1
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- Drug: HTL0009936 matching placebo
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 54
- Registration Number
- NCT02546310
- Locations
- π¬π§
Neuroscience and Psychiatry Unit, Manchester, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath